Characterization of Influenza Vaccine Hemagglutinin Complexes by Cryo-Electron Microscopy and Image Analyses Reveals Structural Polymorphisms

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2016 Apr 15

PMID 27074939

Citations 13

Authors

Dustin M McCraw

John R Gallagher

Audray K Harris

Affiliations

Soon will be listed here.

Abstract

Influenza virus afflicts millions of people worldwide on an annual basis. There is an ever-present risk that animal viruses will cross the species barrier to cause epidemics and pandemics resulting in great morbidity and mortality. Zoonosis outbreaks, such as the H7N9 outbreak, underscore the need to better understand the molecular organization of viral immunogens, such as recombinant influenza virus hemagglutinin (HA) proteins, used in influenza virus subunit vaccines in order to optimize vaccine efficacy. Here, using cryo-electron microscopy and image analysis, we show that recombinant H7 HA in vaccines formed macromolecular complexes consisting of variable numbers of HA subunits (range, 6 to 8). In addition, HA complexes were distributed across at least four distinct structural classes (polymorphisms). Three-dimensional (3D) reconstruction and molecular modeling indicated that HA was in the prefusion state and suggested that the oligomerization and the structural polymorphisms observed were due to hydrophobic interactions involving the transmembrane regions. These experiments suggest that characterization of the molecular structures of influenza virus HA complexes used in subunit vaccines will lead to better understanding of the differences in vaccine efficacy and to the optimization of subunit vaccines to prevent influenza virus infection.

Citing Articles

Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.

Myers M, Conlon M, Gallagher J, Woolfork D, Khorrami N, Park W bioRxiv. 2024; .

PMID: 39372734 PMC: 11451747. DOI: 10.1101/2024.09.12.612748.

Antigen spacing on protein nanoparticles influences antibody responses to vaccination.

Ellis D, Dosey A, Boyoglu-Barnum S, Park Y, Gillespie R, Syeda H Cell Rep. 2023; 42(12):113552.

PMID: 38096058 PMC: 10801709. DOI: 10.1016/j.celrep.2023.113552.

Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes.

McCraw D, Myers M, Gulati N, Prabhakaran M, Brand J, Andrews S PLoS Pathog. 2023; 19(8):e1011514.

PMID: 37639457 PMC: 10491405. DOI: 10.1371/journal.ppat.1011514.

Antigen spacing on protein nanoparticles influences antibody responses to vaccination.

Ellis D, Dosey A, Boyoglu-Barnum S, Park Y, Gillespie R, Syeda H bioRxiv. 2023; .

PMID: 37292995 PMC: 10245855. DOI: 10.1101/2023.05.23.541980.

Characterization of Inactivated Influenza Vaccines Used in the Russian National Immunization Program.

Tarasov M, Shanko A, Kordyukova L, Katlinski A Vaccines (Basel). 2020; 8(3).

PMID: 32872645 PMC: 7564049. DOI: 10.3390/vaccines8030488.

References

Gross P, Ennis F . Influenza vaccine: split-product versus whole-virus types--How do they differ?. N Engl J Med. 1977; 296(10):567-8. DOI: 10.1056/NEJM197703102961012. View

Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z . Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis. 2015; 213(6):922-9. PMC: 4760421. DOI: 10.1093/infdis/jiv526. View

Webster R, Brown L, Jackson D . Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH. Virology. 1983; 126(2):587-99. DOI: 10.1016/s0042-6822(83)80015-4. View

Jin H, Subbarao K . Live attenuated influenza vaccine. Curr Top Microbiol Immunol. 2014; 386:181-204. DOI: 10.1007/82_2014_410. View

Liu Q, Liu K, Xue C, Zhou J, Li X, Luo D . Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. Vaccine. 2014; 32(25):3041-9. PMC: 7115591. DOI: 10.1016/j.vaccine.2014.03.058. View

McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. PMC: 4459498. DOI: 10.1126/science.1234914. View

Xu R, Ekiert D, Krause J, Hai R, Crowe Jr J, Wilson I . Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010; 328(5976):357-60. PMC: 2897825. DOI: 10.1126/science.1186430. View

Gething M, Bye J, Skehel J, Waterfield M . Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus. Nature. 1980; 287(5780):301-6. DOI: 10.1038/287301a0. View

Liljeroos L, Krzyzaniak M, Helenius A, Butcher S . Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A. 2013; 110(27):11133-8. PMC: 3703984. DOI: 10.1073/pnas.1309070110. View

10.

Scheres S . RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012; 180(3):519-30. PMC: 3690530. DOI: 10.1016/j.jsb.2012.09.006. View

11.

Glenn G, Smith G, Fries L, Raghunandan R, Lu H, Zhou B . Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2012; 31(3):524-32. DOI: 10.1016/j.vaccine.2012.11.009. View

12.

McALEER W, BUYNAK E, Maigetter R, WAMPLER D, MILLER W, HILLEMAN M . Human hepatitis B vaccine from recombinant yeast. Nature. 1984; 307(5947):178-80. DOI: 10.1038/307178a0. View

13.

Laver W, Valentine R . Morphology of the isolated hemagglutinin and neuraminidase subunits of influenza virus. Virology. 1969; 38(1):105-19. DOI: 10.1016/0042-6822(69)90132-9. View

14.

Russell R, Gamblin S, Haire L, Stevens D, Xiao B, Ha Y . H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology. 2004; 325(2):287-96. DOI: 10.1016/j.virol.2004.04.040. View

15.

Heymann J, Belnap D . Bsoft: image processing and molecular modeling for electron microscopy. J Struct Biol. 2006; 157(1):3-18. DOI: 10.1016/j.jsb.2006.06.006. View

16.

Harris A, Meyerson J, Matsuoka Y, Kuybeda O, Moran A, Bliss D . Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A. 2013; 110(12):4592-7. PMC: 3607006. DOI: 10.1073/pnas.1214913110. View

17.

Feshchenko E, Rhodes D, Felberbaum R, McPherson C, Rininger J, Post P . Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 2012; 12:77. PMC: 3538074. DOI: 10.1186/1472-6750-12-77. View

18.

Cox M, Patriarca P, Treanor J . FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses. 2009; 2(6):211-9. PMC: 4634115. DOI: 10.1111/j.1750-2659.2008.00053.x. View

19.

Buckland B, Boulanger R, Fino M, Srivastava I, Holtz K, Khramtsov N . Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine. 2014; 32(42):5496-502. DOI: 10.1016/j.vaccine.2014.07.074. View

20.

Lam T, Zhou B, Wang J, Chai Y, Shen Y, Chen X . Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature. 2015; 522(7554):102-5. DOI: 10.1038/nature14348. View